Huntington disease and restless legs syndrome

• Huntington disease (HD) is an autosomal dominant neurodegenerative disorder: one expanded CAG trinucleotide repeat in the huntingtin gene eventually produces chorea, cognitive decline and psychiatric change.
• Repeat size drives much of the story: 36 or more CAG repeats can cause disease, 36 to 39 show reduced penetrance, and 40 or more are usually fully penetrant; a CAG expansion greater than about 60 usually causes juvenile onset. ^[1][2]
• There is no cure. Symptomatic treatment is the mainstay, and an international task force commissioned by the European Huntington Disease Network (EHDN) recommends tetrabenazine or, in some patients, second-generation antipsychotics for chorea.
• Restless legs syndrome (RLS) is a clinical diagnosis: an urge to move the legs at rest that eases with movement and worsens in the evening or at night.
• Current guidance has shifted: the 2025 American Academy of Sleep Medicine (AASM) clinical practice guideline (literature search September 2023, published January 2025) strongly recommends gabapentinoids and intravenous ferric carboxymaltose and advises against routine long-term use of dopamine agonists because of augmentation, although regional guidelines still use dopamine agonists as first-line therapy in some countries. ^[4]

By the end of this page you should be able to:

1. Explain the genetics of Huntington disease, including inheritance, anticipation and penetrance.
2. Relate the selective loss of striatal neurons to chorea and later rigidity.
3. Describe the movement, cognitive and psychiatric features of Huntington disease and recognise juvenile onset.
4. Apply the IRLSSG (International Restless Legs Syndrome Study Group) essential diagnostic criteria to a patient with leg discomfort.
5. Arrange first-line and second-line treatment of restless legs syndrome using current guideline logic, including iron thresholds and augmentation.
6. Recognise differences between major contemporary restless legs syndrome guidelines.
7. Distinguish Huntington disease and restless legs syndrome from their common mimics.

Clinically, Huntington disease is the classic example of a triad: a movement disorder, cognitive decline and psychiatric change, progressing over 16 to 18 years according to Andhale 2022. The structure that is damaged earliest is the striatum, so chorea appears before weakness. ^[1]

Classification matters clinically. Huntington disease is one neurodegenerative chorea among several; its closest mimics are the Huntington phenocopies, especially spinocerebellar ataxia 17 and the C9orf72 expansion in European populations. ^[1] Restless legs syndrome is not a degenerative disease and is diagnosed entirely by history; polysomnography is not required. ^[10] The most influential current named guidelines are the EHDN international guidelines (2019 edition), the IRLSSG diagnostic criteria (2014 edition) and iron-treatment task force (2018 edition), the long-term IRLSSG treatment report (2013 edition), the IRLSSG/EURLSSG/RLS Foundation augmentation task force (2016 edition), the German Sleep Society/German Neurological Society abbreviated guidelines (2024 edition), and the AASM clinical practice guideline (literature search September 2023, published 2025). ^[4][5]

Huntington disease. HD occurs worldwide but shows a strong ethnic gradient. In populations of European descent prevalence is about 10 to 13 per 100,000, whereas in East Asia it is 1 to 7 per million, roughly 10 to 100 times lower. ^[1] In the United Kingdom prevalence is about 1 in 8,000. ^[2] The average age at motor onset is between 35 and 45 years, and the course usually lasts 16 to 18 years; some reviews describe 15 to 20 years. ^[1][2] There is no sex predilection in inheritance, but the repeat is unstable, so a parent with an intermediate allele that can expand into the pathogenic range. Paternal transmission is the main driver of anticipation and of very large expansions. ^[1][2]

Risk factors are almost entirely non-modifiable: the expanded HTT allele, intermediate alleles that can expand in the next generation, and a positive (or hidden) family history. About 10% of positive diagnostic tests are apparently de novo, often because of adoption, estrangement or misdiagnosis in earlier generations. ^[2]

Restless legs syndrome. In large population studies roughly 8% of US adults experience RLS symptoms of any frequency annually, and 3% have moderately or severely distressing symptoms at least twice a week. ^[10] The AASM guideline describes clinically significant RLS (at least twice weekly with at least moderate distress) in 2 to 3% of adults and 0.5 to 1% of children, with adult women affected about 50% more often than men. ^[4] Onset is usually in middle life, although symptoms can begin in childhood; prevalence rises to about 10% in adults aged 65 years or older. Northern European descent, female sex (about 2 to 1), family history, iron deficiency and a range of common chronic diseases are the main risk factors; in particular, RLS affects 24% of people with end-stage kidney disease, 23.9% of those with iron-deficiency anaemia, 27.5% with multiple sclerosis and 20% with Parkinson disease. ^{[10][4] [5]}

Huntington disease. The mutation is a toxic gain of function at the protein level. Mutant huntingtin is cleaved and aggregates, disrupting transcription, axonal transport, mitochondrial function, proteostasis and neuronal signalling. Striatal medium spiny neurons are selectively vulnerable early in the disease, which is why chorea and not weakness dominates the first decade, while cortex, hippocampus and brainstem are affected later. ^[1] Gross pathology follows a caudate and putamen atrophy gradient, with five recognised severity grades at autopsy. ^[1] Anticipation is explained by repeat instability, especially during spermatogenesis, so larger repeats and earlier, more severe disease are more likely when the gene is transmitted by the father. ^[1][2]

Restless legs syndrome. RLS pathophysiology is not completely understood, but three threads are well established: genetic susceptibility, dopaminergic dysfunction and brain iron deficiency. ^[4][5] Brain iron indices are reduced on imaging and cerebrospinal fluid studies, and RLS is over-represented in systemic iron deficiency (pregnancy, end-stage kidney disease), which is why iron treatment is central. ^[4][7] Contemporary guidelines have therefore moved away from the older "primary" and "secondary" labels and instead frame RLS as a multifactorial disorder in which genetic, socioeconomic and environmental factors and comorbidities interact. ^[5] Dopaminergic agents work acutely, yet long-term exposure is the main cause of augmentation, an iatrogenic worsening of the disorder. ^[4]

The hallmark motor symptom is chorea: abnormal, involuntary, spontaneous, irregular, intermittent and non-rhythmic movements that can involve the face, trunk and limbs. ^[1][3] Chorea fluctuates through the day, often reduces during sleep, and usually progresses slowly; patients are often less distressed by it than relatives. ^[2] Other motor problems include dystonia, rigidity, incoordination and eye-movement abnormalities, which together create a large falls risk that grows as the disease advances, and later dysarthria and dysphagia. ^[2] Unintentional weight loss, sleep and circadian disturbance and autonomic features such as excessive sweating are common but less often discussed. ^[1]

The psychiatric picture is prominent and frequently precedes motor onset: apathy, loss of motivation, perseveration, depression, anxiety, irritability, aggressive outbursts and obsessive or compulsive phenomena are all common, with less frequent hallucinations and delusions. ^[2] Rates of substance misuse, self-harm and suicide are higher than in the general population. ^[2] Cognitive change is dominated by executive dysfunction: impaired planning and mental flexibility make previously capable people struggle with everyday organisation. ^[1]

Examination therefore looks for a whole-person syndrome rather than a single sign: chorea and slowed saccades with incomplete ocular pursuit; tongue-protrusion difficulty; dysarthria; rigidity and bradykinesia; distractible, impulsive behaviour; and evidence of cognitive change. ^[2]

Juvenile Huntington disease (onset before 20 years, usually with a very large CAG expansion) presents differently: learning and behavioural problems plus rigidity, bradykinesia and seizures dominate; chorea, if it appears, tends to emerge only in the second decade. ^[1][2]

The patient's own words are the diagnosis: an overwhelming, usually unpleasant urge to move the legs, described as achiness, tingling, burning or insect-like sensations, provoked by rest and relieved by movement, and worst in the evening or at night. ^[4][10] Symptoms disrupt sleep onset and maintenance in roughly 90% of people, and movements in sleep (periodic limb movements of sleep) occur in over 80%, larger than 15 movements per hour. ^[4][5] On examination there is little to find in typical idiopathic RLS beyond ruling out mimics; the neurologic examination is usually normal. ^[5]

Figure 1Huntington

Enlarge

Long description

Coronal MRI (FSPGR) through the brain at the level of the caudate nuclei demonstrating marked reduced volume in a patient with known Huntington disease.

Genetic testing in HD has two contexts, and the counselling requirements differ. Diagnostic testing is offered when a person has symptoms and signs consistent with HD, usually chorea, with or without a family history; about 10% of patients have no known family history. Predictive testing is offered to asymptomatic adults at risk; it requires lengthy pre-test counselling and is not recommended before 18 years. ^[2]

In RLS, the investigation list is deliberately small: a sleep and medication history, iron studies and, where suggestive, renal function and evidence of peripheral neuropathy. Exacerbating factors to ask about include alcohol, caffeine, antidepressants (serotonergic), antihistamines, dopamine antagonists and untreated obstructive sleep apnoea. ^[4][5]

HD management is symptomatic, multidisciplinary and supportive: physicians, specialist nurses, clinical psychologists, psychiatrists, physiotherapists, speech and language therapists and dieticians together aim to protect function and quality of life for as long as possible. ^[2][3] There is no treatment that stops or reverses progression. ^[2]

The EHDN 2019 international guidelines advise that chorea should be treated when it causes distress or functional impairment, and that monotherapy is preferred because combination therapy increases adverse effects and complicates care of non-motor symptoms. ^[3] They name tetrabenazine as one first-line treatment for chorea (Grade A), unless the patient has poorly managed depression or suicidal thoughts, and second-generation (atypical) antipsychotics such as risperidone, quetiapine or olanzapine (Grade B) as first-line when the patient also has behavioural or psychotic symptoms. ^[1][3]

Three current concepts govern RLS treatment. First, exacerbating factors come before drugs. ^[4] Second, untreated iron deficiency should be corrected. ^[4][7] Third, the role of dopamine agonists has changed: they are now advised only when a patient values short-term relief more than the long-term risk of augmentation. ^[4][10] The named editions are important: the AASM clinical practice guideline uses a literature search through September 2023 and was published in January 2025; the comprehensive German abbreviated guidelines were published in 2024; and the IRLSSG long-term report and augmentation task force were published in 2013 and 2016. ^{[4][5] [8]}

Iron is usually the first pharmacological step when iron indices are low. The AASM good practice statement sets adult thresholds of serum ferritin at most 75 ng/mL, or ferritin between 75 and 100 ng/mL with an intravenous-only approach, and transferrin saturation under 20%, with ferritin under 50 ng/mL in children. ^[4] The IRLSSG iron task force adds evidence that intravenous ferric carboxymaltose 1000 mg is effective in adults with serum ferritin under 300 microg per litre, and that oral iron 65 mg elemental iron may help when ferritin is at most 75 microg per litre. ^[7] A recent review recommends ferrous sulfate 325 to 650 mg daily or every other day, or intravenous iron 1000 mg, for ferritin up to 100 ng/mL or transferrin saturation under 20%. ^[10] The German guidelines instead treat ferritin at most 75 microg per litre with oral iron in mild RLS, intravenous iron for moderate-to-severe disease or poor tolerance, and ferric carboxymaltose 1000 mg as a single intravenous dose in selected patients. ^[5] This is a genuine guideline disagreement on thresholds, not a misunderstanding. ^{[4][5][7][10]}

Gabapentinoids are the new first-line drug class. The AASM guideline gives strong recommendations for gabapentin enacarbil, gabapentin and pregabalin; in trials about 70% of patients treated with gabapentinoids were much or very much improved versus about 40% with placebo. ^[4][10] The German guidance uses gabapentin or pregabalin as initial therapy (off-label in many European countries), starting pregabalin at 50 to 75 mg and titrating to 150 to 450 mg in a single evening dose, and titrating gabapentin up to a maximum of 1800 mg daily in divided doses, with uremic RLS treated with 200 mg. ^[5] Evidence for long-term use comes from the IRLSSG 2013 report: pregabalin up to one year (Level A), pramipexole, ropinirole and rotigotine up to six months (Level A). ^[8]

Dopamine agonists remain useful but have moved to second-line. The German guidelines still regard pramipexole, ropinirole and the rotigotine patch as first-line for moderate-to-severe RLS in Germany, Austria and Switzerland, and require the lowest effective dose: pramipexole start 0.18 mg, maximum 0.52 mg; ropinirole start 0.25 mg, target 2 mg, maximum 4 mg; rotigotine patch approved 1 to 3 mg, commonly 2 mg. ^[5] Levodopa is restricted to intermittent use, maximum 100 mg, because augmentation is common, especially at daily doses of 200 mg or more. ^[5] By contrast the AASM gives conditional recommendations against standard long-term use of levodopa, pramipexole, ropinirole and transdermal rotigotine because of augmentation, while explicitly allowing short-term use when a patient prefers symptom relief over long-term risk. ^[4] A recent review notes that dopamine agonists carry an augmentation incidence of 7 to 10% per year, lower with the rotigotine patch than with oral agonists. ^[10] The combined IRLSSG task force recommended using an alpha-2-delta ligand initially to prevent augmentation, or, if a dopamine agonist is chosen, the lowest possible dose, with iron stores corrected first. ^{[9] [8]}

Other options in refractory disease include extended-release oxycodone/naloxone, approved since 2014 from 5/2.5 mg twice daily up to 30/15 mg twice daily, with careful respiratory monitoring and a note to avoid serotonergic opioids; intravenous iron when oral iron fails; peroneal nerve stimulation; and, in pregnancy, oral iron when ferritin is at most 75 microg per litre, with low-dose oxycodone/naloxone 5 to 20 mg daily or low-dose clonazepam reserved for very severe refractory cases. ^[4][5][10]

Augmentation is the most important long-term complication. The diagnostic clues are an advance of RLS symptoms by about 2 hours, spread to other body areas, increased intensity compared with baseline, and loss of medication effect, after excluding mimics such as cramps and opioid-induced hyperalgesia. ^[4][5] Management is stepped: correct iron deficiency, reduce the dopamine agonist to the approved maximum and divide doses, switch from levodopa to a dopamine agonist, and from a dopamine agonist to long-acting rotigotine or an opioid, often with very slow tapering to avoid withdrawal. ^[5][9] Avoiding augmentation means treating with an alpha-2-delta ligand first, or using the smallest possible dose of a dopamine agonist. ^[5][9]

Complications are mainly the consequences of progression rather than of treatment. Aspiration pneumonia and other lung infections are the leading cause of death; suicide is second. ^[1] Chorea and rigidity lead to falls, trauma, fractures and dysphagia; executive failure and loss of insight create financial, relational and safety risks; sleep and circadian disturbance worsen every other symptom. ^[1][2] Medication complications follow the profile of the drugs used: dopamine depletion can worsen mood and sleep, and antipsychotics can produce sedation and weight gain. ^[1][2]

The main RLS complication is augmentation, iatrogenic worsening over months to years of dopaminergic exposure. ^[4] Patients also suffer insomnia, daytime somnolence, depression and reduced quality of life; treated RLS with persisting augmentation can require hospitalisation to withdraw medication safely. ^[5] Escalating doses in response to augmentation itself worsens the problem, which is why dose ceilings matter. ^[4][5]

Huntington disease is fatal, with a course usually reported as 16 to 18 years. Life expectancy is shortened by about 13.3 years on average. ^[1][2] Death is most often from pneumonia or aspiration and, for some, from suicide. ^[1][2] Repeat size predicts age of onset and severity but not an individual life span, and homozygosity does not substantially change onset compared with heterozygosity. ^[1][2]

RLS is not a degenerative or fatal condition. Symptoms fluctuate over life, sometimes starting in childhood, often peaking in middle age, sometimes worsening with pregnancy or iron loss, and sometimes remitting. ^[4][10] Quality of life and sleep are strongly affected, and comorbidity associations (cardiovascular, psychiatric) are reported, although these do not make RLS itself life-shortening. ^[10] With appropriate iron repletion and non-dopaminergic therapy most patients do well. ^[4][5]

There is no primary prevention. The practical preventive tools are predictive and prenatal ones, used cautiously: cascade testing with pre-test counselling for adults at risk, and prenatal or pre-implantation genetic diagnosis for families who request it. ^[2] Children are not tested for an adult-onset condition without clinical indication. ^[2] Genetic testing should always be via an authorised laboratory with genetic counselling, not direct-to-consumer testing, because of the ethical weight of a positive result. ^[2]

Secondary prevention is practical prevention of triggers: correct iron deficiency, avoid serotonergic antidepressants, dopamine antagonists and centrally acting antihistamines where possible, treat obstructive sleep apnoea, and reduce alcohol and excess caffeine. ^[4][10] Screening questionnaires exist, but diagnosis remains clinical, and polysomnography is not a screening tool. ^[4][10]

Children with RLS are diagnosed with the same five essential criteria adapted for age, and iron studies matter: ferritin under 50 ng per mL is the treatment threshold, with oral or intravenous iron. ^[4][5] Paediatric RLS prevalence is 0.5 to 1% and describing symptoms can be difficult. ^[4] Juvenile HD presents with learning, behavioural, rigid and hyperkinetic features rather than chorea, and is associated with large expansions, usually over 60 CAG repeats. ^[1][2]

RLS is common in pregnancy, especially the third trimester, affecting roughly 22% of pregnancies. ^[10] Iron should be replaced when ferritin is at most 75 microg per litre. ^[5] If medication is needed, prescribers should choose by pregnancy-specific safety; gabapentin and pregabalin are not recommended because of animal data, while low-dose oxycodone/naloxone or, in the second and third trimesters, low-dose clonazepam, can be reserved for very severe refractory cases. ^[4][5] In HD, pregnancy management rests on accurate genetic and neurological counselling rather than disease-specific drug regimens. ^[2]

RLS prevalence rises to about 10% in adults aged 65 years or older, and alpha-2-delta ligands in particular can cause dizziness, peripheral oedema, gait imbalance and visual disturbance in older patients. ^[5][10] In HD, onset can occur outside the usual 35-to-45 window across a reported range of 2 to 80 years, but the management principles remain the same: multidisciplinary support, chorea treatment if disabling, and attention to swallowing, nutrition and falls. ^[1][2]

Where advanced care is not available, HD diagnosis can still be anchored on a characteristic family history and clinical phenotype, with genetic testing in a recognised laboratory if possible; support, swallowing care, nutrition, physiotherapy and psychiatric care remain the main treatment everywhere. ^[2] For RLS, diagnosis requires only a good history and iron studies; oral iron and the lowest effective doses of available antiparkinsonian or antiepileptic agents, with careful clinical review for augmentation, are pragmatic options. ^[4][5]

Excluding mimics is not a footnote: the fifth IRLSSG essential criterion for RLS exists precisely because positional discomfort, cramps, arthritis, neuropathy and drug effects can look identical until they are excluded. ^[5][6]

• Huntington disease is an autosomal dominant disorder with a 50% transmission risk and full penetrance with 40 or more CAG repeats. ^[2]
• Repeat expansion drives anticipation; paternal transmission explains most very large expansions and juvenile onset.
• Striatal degeneration converts into chorea early and rigidity later, so the movement picture changes across the disease.
• Psychiatric and executive symptoms often precede motor onset and dominate quality of life.
• There is no disease-modifying treatment; multidisciplinary supportive care is the core.
• EHDN 2019 guidance names tetrabenazine (Grade A) and, in some patients, second-generation antipsychotics (Grade B) for chorea.
• Restless legs syndrome is a clinical diagnosis with five IRLSSG essential criteria; there is no laboratory or imaging test.
• Diagnosis requires careful exclusion of mimics; polysomnography supports but is not required.
• Iron status determines treatment: replace iron when ferritin is low or iron stores are borderline, using oral or intravenous routes according to severity and tolerance.
• Contemporary guidelines disagree honestly: AASM strongly recommends gabapentinoids and advises against routine long-term dopamine agonists, while German guidelines still use dopamine agonists as first-line with strict dose ceilings.
• Dopamine agonist augmentation has an annual incidence of 7 to 10% and is the main reason for dose limitation and stepwise withdrawal. ^[10]
• Evidence for long-term RLS therapy is strongest for pregabalin up to one year and for dopamine agonists up to six months.
• Predictive genetic testing in Huntington disease is for adults with counselling; children should not be tested for an adult-onset condition without clinical indication.

No additional verified MedGrasp topics are listed for this page.